Allene M. Diaz, a member of the board of directors at Ionis Pharmaceuticals Inc (NASDAQ: IONS), completed a set of stock transactions on March 3, 2026, that included the sale of common shares and the exercise of previously held options.
Share sales and pricing
Diaz sold a total of 54,878 shares of Ionis common stock across multiple transactions on March 3, 2026. The sales were executed at prices ranging from $79.114 to $80.799 per share, resulting in aggregate proceeds of approximately $4.35 million. At the time of reporting, Ionis shares were trading at $75.16, below the prices at which the director sold.
Option exercises
In addition to the open-market sales, Diaz exercised options to acquire 40,321 shares of Ionis common stock. The strike prices on those options ranged from $38.06 to $41.08, and the option exercises had a total value of $1601606.
Holding and plan details
The sales were carried out under a Rule 10b5-1 trading plan that Diaz adopted on November 25, 2025. Following these transactions, Diaz directly owns 3,811 shares of Ionis Pharmaceuticals.
Company performance and expectations
Despite the director-level selling at higher levels, Ionis shares have delivered strong returns over the last year, rising 122.7 percent. Notwithstanding that performance, an InvestingPro analysis cited in the company reporting indicates Ionis is not expected to be profitable this year.
Clinical and regulatory developments
Separately from the insider transactions, Ionis has continued to advance its clinical and regulatory agenda. The U.S. Food and Drug Administration has accepted a supplemental New Drug Application for olezarsen, a therapy targeting severe hypertriglyceridemia, and has set a target decision date of June 30, 2026. The application is supported by Phase 3 trials that demonstrated meaningful reductions in triglyceride levels and in acute pancreatitis events.
Ionis is also presenting new data on DAWNZERA, its treatment for hereditary angioedema, at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
Analyst actions
Following recent developments, several analyst firms have adjusted their price targets for Ionis. Bernstein raised its target to $90, citing confidence in forthcoming Phase 3 results. Stifel increased its target to $77 while noting a cautious stance in light of below-expectation topline guidance for 2026. Morgan Stanley set a new target of $95, pointing to strong commercial execution despite softer guidance for the upcoming year. These target revisions underscore continued analyst attention on Ionis amid its clinical and commercial progress.
Note on scope
The reporting above reflects disclosed transactions and company announcements as presented in filings and company statements. It does not add or infer facts beyond those disclosures.